|MDACC Study No:||2012-0171LEUKEMIA (clinicaltrials.gov NCT No: NCT01539291)|
|Title:||A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia|
|Principal Investigator:||William G. Wierda|
|Treatment Agent:||GS-1101; Rituximab|
|Study Description:||The goal of this clinical research study is to allow you to continue receiving |
or start receiving idelalisib for as long as the study doctor thinks it is in
your best interest. This extension study will continue to study whether
idelalisib can help to control CLL. The long-term safety of this drug will
also continue to be studied.
Idelalisib is designed to block some of the cell functions that cause CLL cells
to grow and survive.